BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Botensilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Botensilimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06300463-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06300463)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Platform St
 udy of Immunotherapy Combinations in Colorectal Cancer Liver Metastases\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06300463
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128355-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Botensilimab: Phase 1 readout est. (NCT07128355)
DESCRIPTION:Botensilimab\, phase 1\, Colorectal Cancer.\nStudy: Botensilima
 b\, Balstilimab\, and SBRT in Colorectal Cancer\nEstimated primary complet
 ion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 botensilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07128355
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06336902-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Botensilimab: Phase 1 readout est. (NCT06336902)
DESCRIPTION:Botensilimab\, phase 1\, Colorectal Cancer.\nStudy: Botensilima
 b Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients 
 With KRAS-Mutant Metastatic Colorectal Cancer\nEstimated primary completio
 n: 15 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 otensilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06336902
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04028063-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Botensilimab: Phase 2 readout est. (NCT04028063)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: Doxorubicin Plus Dual Checkpoin
 t Blockade for Soft Tissue Sarcomas\nEstimated primary completion: 7 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/botensilimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04028
 063
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Botensilimab: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Pre-operati
 ve Targeted Treatments in Molecularly Selected Resectable Colorectal Cance
 r (UNICORN)\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735624-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07735624)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: RECTIFY-1: Neoadjuvant Botensil
 imab + Balstilimab in MSS/pMMR Early Rectal Cancer\nEstimated primary comp
 letion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 botensilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07735624
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627635-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:Botensilimab: Phase 1/2 readout est. (NCT05627635)
DESCRIPTION:Botensilimab\, phase 1/2\, Colorectal Cancer.\nStudy: FOLFOX an
 d Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX)
  for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Ca
 ncer\nEstimated primary completion: 16 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05627635
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589440-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06589440)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Phase 2 Stu
 dy of SR-8541A in Combination With Botensilimab and Balstilimab in Subject
 s With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-
 CRC)\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06589440
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251973-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06251973)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: A Study of agenT-797 in Combina
 tion With Botensilimab\, Balstilimab\, Ramucirumab\, and Paclitaxel for Pe
 ople With Esophageal\, Gastric\, or Gastro-esophageal Junction Cancer\nEst
 imated primary completion: 1 August 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06251973
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608044-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Botensilimab: Phase 2 readout est. (NCT05608044)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: A Study of 
 Botensilimab and Balstilimab for the Treatment of Colorectal Cancer\nEstim
 ated primary completion: September 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05608044
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780787-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06780787)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: FOLFOX\, Botensilimab\, and Bal
 stilimab for the Treatment of Localized Rectal Cancer Before Surgery\nEsti
 mated primary completion: 5 November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06780787
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843434-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06843434)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: A Study of Botensilimab and Bal
 stilimab for Rectal Adenocarcinoma\nEstimated primary completion: 20 Febru
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/botensilima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 843434
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193862-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Botensilimab: Phase 1 readout est. (NCT07193862)
DESCRIPTION:Botensilimab\, phase 1\, Colorectal Cancer.\nStudy: Pilot Study
  of an Implantable Microdevice for In Situ Evaluation of Drug Response in 
 Patients With Colorectal Liver Metastasis\nEstimated primary completion: 1
 5 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/botensi
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07193862
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06346197-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Botensilimab: Phase 3 readout est. (NCT06346197)
DESCRIPTION:Botensilimab\, phase 3.\nStudy: Combination of Immune Checkpoin
 t in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas\nE
 stimated primary completion: 15 May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06346197
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268015-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06268015)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Botensilima
 b and Balstilimab Optimization in Colorectal Cancer\nEstimated primary com
 pletion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 otensilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06268015
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550088-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07550088)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: BAL/BOT/age
 nT-797 in pMMR CRC With Liver Metastases\nEstimated primary completion: Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/botensi
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07550088
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595874-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07595874)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvant
  Botensilimab and Balstilimab for the Treatment of Advanced Resectable Col
 orectal Cancer NEST3\nEstimated primary completion: 16 December 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/botensilimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07595874
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516366-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07516366)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: Testing the Safety and Feasibil
 ity of Immunotherapy Drugs\, Botensilimab and Balstilimab\, Before Surgery
  for Clear Cell Renal Cell Carcinoma\, NEO RoBOT Trial\nEstimated primary 
 completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/botensilimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07516366
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279130-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Botensilimab: Phase 2/3 readout est. (NCT06279130)
DESCRIPTION:Botensilimab\, phase 2/3.\nStudy: Pan-tumor Neoadjuvant Basket 
 Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinati
 ons\nEstimated primary completion: 29 January 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06279130
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578337-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07578337)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: A Clinical Study Evaluating a N
 ew Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Hav
 e Not Received Prior Treatment for Advanced Disease.\nEstimated primary co
 mpletion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/botensilimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07578337
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551596-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20290828
DTEND;VALUE=DATE:20290829
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07551596)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: Testing the
  Combination of Anti-Cancer Drugs\, Botensilimab (AGEN1181) and Balstilima
 b (AGEN2034)\, After Standard Treatment for Colorectal Cancer\, Combat Tri
 al\nEstimated primary completion: 28 August 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07551596
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06411691-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Botensilimab: Phase 1 readout est. (NCT06411691)
DESCRIPTION:Botensilimab\, phase 1\, Colorectal Cancer.\nStudy: KRAS-Target
 ed Vaccine Combined With Balstilimab and Botensilimab for Patients With St
 age IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer\nEstimated pri
 mary completion: 1 November 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/botensilimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06411691
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06322108-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06322108)
DESCRIPTION:Botensilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: As
 sessment of the Safety and Efficacy of Balstilimab in Combination With Bot
 ensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)\nEs
 timated primary completion: April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06322108
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843551-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06843551)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: The Miami "EMPIRE" Trial - Erad
 ication of Metastatic Pancreatic Cancer With Immuno-Radiation\nEstimated p
 rimary completion: 1 August 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/botensilimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06843551
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227636-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Botensilimab: Phase 2 readout est. (NCT07227636)
DESCRIPTION:Botensilimab\, phase 2\, Colorectal Cancer.\nStudy: A Study of 
 Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surge
 ry and Chemotherapy\nEstimated primary completion: November 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/botensilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07227636
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05864534-2415@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Botensilimab: Phase 2 readout est. (NCT05864534)
DESCRIPTION:Botensilimab\, phase 2.\nStudy: Phase 2a Immune Modulation With
  Ultrasound for Newly Diagnosed Glioblastoma\nEstimated primary completion
 : 31 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/boten
 silimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05864534
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
